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Abstract 
Background: Restoring and maintaining sinus rhythm (SR) in patients with atrial fibrillation 
(AF) failed to show superior outcomes over rate control strategies in prior randomized trials. 
However, there is sparse data on their outcomes in patients with acute heart failure (AHF). 
Methods: From December 2010 to February 2014, 5,625 patients with AHF from 10 tertiary 
hospitals were enrolled in the Korean Acute Heart Failure registry, including 1,961 patients 
whose initial electrocardiogram showed AF. Clinical outcomes of patients who restored sinus 
rhythm by pharmacological or electrical cardioversion (SR conversion group, n = 212) were 
compared to those of patients who showed a persistent AF rhythm (AF persistent group, n = 
1,662). 
Results: All-cause mortality both in-hospital and during the follow-up (median 2.5 years) 
were significantly lower in the SR conversion group than in the AF persistent group after 
adjustment for risk factors (adjusted hazard ratio [HR]; 95% confidence interval [CI] = 0.26 
[0.08–0.88], p = 0.031 and 0.59 [0.43–0.82], p = 0.002, for mortality in-hospital and during 
follow-up, respectively). After 1:3 propensity score matching (SR conversion group = 167, 
AF persistent group = 501), successful restoration of sinus rhythm was associated with lower 
all-cause mortality (HR [95% CI)] = 0.68 [0.49–0.93], p = 0.015), heart failure 
rehospitalization (HR [95% CI)] = 0.66 [0.45–0.97], p = 0.032), and composite of death and 
heart failure rehospitalization (HR [95% CI)] = 0.66 [0.51–0.86], p = 0.002).  
Conclusions: Patients with AHF and AF had significantly lower mortality in-hospital and 
during follow-up if rhythm treatment for AF was successful, underscoring the importance of 
restoring sinus rhythm in patients with AHF. 
Keywords: atrial fibrillation, acute heart failure, cardioversion 
 
 
INTRODUCTION 
Atrial fibrillation (AF) and heart failure (HF) are very prevalent cardiovascular 
diseases resulting in enormous healthcare expenditures and patient suffering. They share risk 
factors, often coexist, and affect each other’s outcomes [1–3]. Therefore, the importance for 
the proper management of AF in patients with HF is growing. Rhythm control strategies for 
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AF management — restoring and maintaining sinus rhythm — failed to show superior 
outcomes in terms of mortality in prior randomised trials. In the AFFIRM trial, around 4,000 
patients with AF and risk factors for stroke or death were randomised and treated either with 
rhythm control or rate control strategies, and it was suggested that rate control strategies 
might be potentially advantageous because of their lower risk of adverse drug effects. 
However, it was also suggested that rhythm control strategies might be beneficial in higher 
risk patients with AF [4]. In the AF-CHF trial, patients with both AF and chronic HF were 
enrolled, and it also failed to show a superior impact of rhythm control strategies over rate 
control strategies [5]. However, there are limited data on the impact of conversion to sinus 
rhythm from AF in patients with acute heart failure (AHF). The aim of this study was to 
investigate the outcomes after rhythm treatment in patients with AHF and AF. 
 
METHODS 
Study population and Korean Acute Heart Failure registry 
The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter 
cohort study that is currently ongoing. Patients are consecutively enrolled upon initial 
hospital admission for AHF syndrome and are followed up accordingly. The registry is 
accumulating data on individual patients, not individual hospitalizations. Information on the 
objectives of the study design and study population is provided in the clinical trial registration 
(ClinicalTrial.gov NCT01389843), and the design and the purpose of the KorAHF registry 
have been published elsewhere [6, 7]. Among a total of 5,625 patients with AHF enrolled in 
this registry, the initial electrocardiograms of 1,933 patients showed AF. Excluding 87 
patients who spontaneously converted to sinus rhythm (SR) without any rhythm treatment, 
herein, 212 patients were compared who had restoration of sinus rhythm and its maintenance 
until discharge (SR conversion group) with 1662 patients who showed a persistent AF rhythm 
(AF persistent group). The study population flow diagram is presented in Figure 1. The study 
protocol was approved by the ethics committee or institutional review board at each hospital 
(IRB No. B-1104-125-014). The need for written informed consent was waived by the 
institutional review board. The study complied with the Declaration of Helsinki. 
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Rhythm treatment for atrial fibrillation 
Restoration of sinus rhythm as well as the modality of rhythm treatment in patients 
with AHF and AF were left to the individual physician’s choice. Both electrical (n = 38) and 
pharmacological cardioversion (n = 174) were included as adequate rhythm treatment. When 
AF spontaneously converted to sinus rhythm, the patient was excluded from the analysis.  
 
Clinical follow-up and endpoints 
The attending physician completed a web-based case report form in the Clinical Data 
Management System (iCReaT) from the Korea National Institute of Health (NIH) with the 
assistance of a clinical research coordinator. The latest information on patient clinical 
manifestation, biochemistry, and medication was collected at the first follow-up visit at 30 
days and again at follow-up visits at 3, 6, 12, 24, 36, 48, and 60 months. The follow-up data 
were collected from the patients by the attending physician and stored in the web-based case 
report form. The outcome data on subjects who were not followed-up were ascertained by 
telephone interview. In addition, the outcome data on patients lost to follow-up were 
collected from the National Death Records. The primary endpoint of this study was the all-
cause mortality rate. The in-hospital outcomes, especially in-hospital mortality were also 
evaluated. All deaths were considered cardiac unless a definite non-cardiac cause could be 
established. All outcome data reported from the participating centers were reviewed by an 
independent clinical event adjudicating committee. 
 
Statistical analysis 
The Student t-test and chi-square or the Fisher exact test were used to compare 
means and proportions of baseline clinical characteristics between the two groups. To address 
potential sources of bias and confounding factors in this retrospective study, propensity 
analysis was performed. Baseline clinical characteristics were incorporated into a non-
parsimonious logistic regression model to compute the propensity score for AF rhythm 
treatment. The included covariates were age, sex, diabetes, hypertension, ischemic heart 
disease, cerebrovascular disease, chronic kidney disease, malignancy, serum hemoglobin and 
creatinine levels, high B-type natriuretic peptide (BNP, > 500 pg/mL) or N-terminal pro-BNP 
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(NT-proBNP, > 1000 pg/mL), left ventricular ejection fraction (LVEF), type of HF (de novo 
vs. acute decompensated), tachycardia as an etiology of AHF, new-onset AF, admission to the 
intensive care unit (ICU), and mechanical ventilation support (C-statistics = 0.739). 1:3 
propensity score-matching iteration were then performed from the fifth digit to the first digit 
and 167 patients with restoration of sinus rhythm were matched to 501 patients with 
persistent AF. Baseline characteristics of the two groups were compared again in this matched 
population. The Cox proportional hazard model was used to estimate the hazard ratio (HR) 
and 95% confidence interval (95% CI) for the clinical outcomes of the two groups. All of the 
statistical analyses were performed using R version 3.6.0, and p < 0.05 was considered 
statistically significant. 
 
RESULTS 
Baseline characteristics 
Baseline clinical characteristics of the overall study population and propensity score-
matched population are shown in Table 1. An SR was more frequently restored in relatively 
younger patients with lower CHA2DS2-VASc scores. Hypertension and chronic kidney 
disease tended to be more prevalent in the AF persistent group. The proportion of new-onset 
AF, de novo HF, and elevated BNP (or NT-proBNP) was higher in the SR conversion group. 
The SR conversion group included more patients who were admitted to ICU or had 
mechanical ventilator support. The LVEF was significantly lower and the left atrium (LA) 
dimension was smaller in the SR conversion group. These parameters were all comparable 
between the groups after propensity score matching. 
 
In-hospital outcomes 
The median duration of hospitalization was 8 days (interquartile range [IQR], 5–13), 
and overall in-hospital mortality was 4.2% in patients with AHF presenting with AF. The 
median duration of hospitalization was 11 days (IQR, 7–19) in the SR conversion group and 
7 days (IQR, 5–13) when AF persisted. Comparisons of in-hospital outcomes between the SR 
conversion and AF persistent groups are presented in Table 2. In-hospital all-cause mortality 
was 4.2% in both groups (unadjusted odds ratio [OR], 95% confidence interval [95% CI] = 
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1.01 [0.44–2.07], p = 0.982), but after adjustment for age, sex, comorbidities, type of HF, 
new-onset AF, laboratory tests, echocardiographic parameters, ICU admission, and 
mechanical ventilation, all-cause mortality was significantly lower in the SR conversion 
group than in the AF persistent group (adjusted OR [95% CI] = 0.26 [0.08–0.88], p = 0.031). 
Cardiovascular mortality and cerebral vascular events were not different between the two 
groups, regardless of the adjustments. After propensity score matching, the overall mortality 
was 2.4% in SR restored patients and 5.9% in AF persisted patients (OR [95% CI] = 0.39 
[0.10–1.00], p = 0.050). Cardiovascular mortality and the incidence of cerebral vascular 
accident were not significantly different between the SR conversion and AF persistent 
groups. 
 
Mortality and HF rehospitalization during Follow-up 
The overall mortality rates at 1, 2, and 3-year follow-up were 18.9%, 23.6%, and 
27.2% when SR was successfully restored, and 22.9%, 31.3%, and 38.2% when AF persisted, 
respectively. The median follow-up duration was 2.5 years. Univariate survival analysis 
indicated that old age and various co-morbidities significantly increased the risk of death 
after AHF. Type of AHF (de novo vs. acute decompensated HF), timing of AF onset (newly 
diagnosed vs. previously diagnosed), laboratory tests, and discharge medications were also 
significantly correlated with mortality (Table 3). The SR conversion group showed 
significantly lower mortality than the AF persistent group in both the unadjusted (unadjusted 
HR [95% CI] = 0.70 [0.54–0.91], p = 0.007) and adjusted analysis (adjusted HR [95% CI] = 
0.59 [0.43–0.82], p = 0.002). HF rehospitalization rate tended to be lower in the SR 
conversion group (unadjusted HR [95% CI] = 0.60 [0.47–0.77], p = 0.001; adjusted HR [95% 
CI] = 0.72 [0.49–1.05], p = 0.084). The composite of death and HF rehospitalization rate was 
lower in the SR conversion group than in the AF persistent group (unadjusted HR [95% CI] = 
0.60 [0.47–0.77], p = 0.001; adjusted HR [95% CI] = 0.65 [0.49–0.85], p = 0.002). Kaplan-
Meier curves for cumulative incidences of outcome events are presented in Figure 2.  
After propensity score matching, all-cause mortality was still significantly lower in 
the SR conversion group (HR [95% CI] = 0.68 [0.49–0.93], p = 0.015). HF rehospitalization 
and the composite of mortality and HF rehospitalization were also lower in the SR group than 
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in the AF persistent group (HF rehospitalization: HR [95% CI] = 0.66 [0.45–0.97], p = 0.032, 
composite of mortality/HF rehospitalization: HR [95% CI] = 0.66 [0.51–0.86], p = 0.002). 
(Fig. 3). 
In subgroup analysis, successful SR conversion was significantly associated with 
lower mortality rate in patients with hypertension, in contrast to patients without 
hypertension, where there was no difference in mortality between the SR conversion and AF 
persistent group (interaction p = 0.021). Other than hypertension, the beneficial effect of 
successful SR conversion for patients with AHF and AF did not, in terms of mortality, 
significantly differ according to age, sex, diabetes mellitus, onset of AF, and the type or 
aetiology of HF (Table 4). 
 
Cerebrovascular events during follow-up 
Cerebrovascular accident rates at the 3-year follow-up were 3.1% when SR was 
restored and 2.3% when AF persisted (HR [95% CI] = 1.28 [0.50–3.28], p = 0.614) in the 
crude study population. After propensity score matching, cerebrovascular event rates were 
3.3% and 3.1% (HR [95% CI] = 1.28 [0.44–3.67], p = 0.652), respectively. 
 
DISCUSSION 
The benefit of rhythm control over rate control strategies in patients with AF has 
been controversial thus far in terms of mortality [4, 5, 8, 9]. Therefore, the current guidelines 
recommend restoration and maintenance of SR mainly in patients with symptomatic AF [10]. 
However, very high-risk patients with AF, such as the patients with AHF in the present study, 
have not been adequately evaluated. The data showed a significantly lower in-hospital 
mortality rate when initial AF was successfully converted to SR either by drugs or electrical 
cardioversion in patients with AHF after adjustments for various covariates. And 
interestingly, this beneficial effect on mortality persisted during the long-term follow-up. The 
HF readmission rate was also lower in the SR conversion group in the matched population. 
There was no significant difference in terms of cerebrovascular events, both in-hospital and 
during follow-up. 
Atrial fibrillation and HF are two very prevalent cardiovascular diseases, often 
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considered to be epidemic [1, 11]. These two cardiovascular diseases share many risk factors, 
such as ageing, hypertension, diabetes mellitus, and underlying ischemic/valvular heart 
disease. Moreover, AF and HF can aggravate each other. There are several suggested 
mechanisms by which AF facilitates the development of HF. First, AF decreases cardiac 
output not only because of the consequences of poor ventricular rate control but also those of 
irregular ventricular filling and loss of atrial contraction. Decreased cardiac output augments 
neuro-hormonal activation observed in HF. Functional mitral annular enlargement is another 
possible explanation for HF development in patients with AF. On the other hand, HF can also 
cause AF development through atrial enlargement, vasoconstrictive neuro-hormonal milieu, 
and atrial fibrosis [1, 12]. These interconnections between AF and HF lead to a high 
prevalence of AF in patients with HF [13], which was 27% in this KorAHF registry. 
Beyond its high prevalence, there is evidence that AF involves increased adverse 
events in patients with congestive HF. In participants of the Framingham Heart Study, AF and 
HF showed a temporal association, and concomitant AF and HF resulted in a lower survival 
rate [14]. Retrospective post-hoc analysis of the SOLVD (Studies of Left Ventricular 
Dysfunction) Prevention and Treatment trials demonstrated that the presence of AF increased 
the risk of all-cause mortality in patients with left ventricular systolic dysfunction [15]. A 
recent meta-analysis of randomised trials concluded that AF increased adverse events in 
patients with chronic HF after adjusting for other clinical risk factors (adjusted OR 1.40) [16]. 
Regarding the timing of AF and HF diagnosis, a community-based study suggested that the 
negative effect of AF on patients with HF was greater with incident AF than with prevalent 
AF [17]. The Framingham cohort [14] and MADIT II (Multicenter Automatic Defibrillator 
Trial II) trial demonstrated supporting results [18].  
On the other hand, the impact of concomitant AF in patients presenting with AHF 
syndrome appears less clear. In contrast to the results from patients with chronic HF, data 
from the ATTEND registry showed no difference in 30-day all-cause mortality between 
patients with (3.04%) or without AF (3.88%) [13]. Additionally, in the KorAHF registry, the 
in-hospital all-cause mortality of the AF population (4.2%) was not different from that of the 
overall population (5.3%). These results might suggest that AF is not a worse etiology or 
more aggravating factor for AHF syndrome than other etiologic factors, although AF is a 
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significant risk factor for adverse outcomes in patients with chronic HF. 
Despite the increase in adverse events by the presence of AF in patients with 
congestive HF, large randomized trials such as the AF-CHF (Atrial Fibrillation and 
Congestive Heart Failure) study [5] and DIAMOND-CHF trial (Danish Investigations of 
Arrhythmia and Mortality on Dofetilide in Congestive Heart Failure) [19] demonstrated no 
benefit of a rhythm control strategy in those patients. However, this result was often 
accounted for by the adverse effects of anti-arrhythmic drugs, especially in AF patients with 
left ventricular dysfunction, and the benefit of maintaining sinus rhythm itself was not 
completely denied. Maintaining sinus rhythm using catheter ablation has been reported to 
improve functional capacity and LVEF compared with the rate control strategy [20–22], and 
more recent trials demonstrated a survival benefit of catheter ablation in patients with AF and 
chronic HF, emphasising the importance of maintaining sinus rhythm itself [23–25]. Data 
herein, also suggest the importance of attempts to maintain SR in AF patients with an acute 
setting of HF. 
In the setting of AHF with AF, benefits of the restoration of SR have not been 
adequately evaluated, perhaps because of difficulties in conducting large randomized clinical 
trials in this population. In the KorAHF registry, all-cause mortality was significantly lower 
when initial AF was converted to SR either by drug (amiodarone) or electrical cardioversion 
in patients with AHF. Despite emerging evidence for the benefit of catheter ablation in 
patients with AF and congestive HF, performing catheter ablation is not widely accepted in 
the setting of AHF syndrome. Therefore, the present study data may reflect the clinical 
outcomes of rhythm control strategies in a daily practice setting. In this study, there was no 
difference in in-hospital mortality irrespective of whether AF persisted or successful 
conversion to SR was acquired in the overall population. However, after adjustments for 
various clinical predictors for mortality, in-hospital mortality was significantly better in the 
SR conversion group. Interestingly, the beneficial effect of conversion to SR in patients with 
AHF and AF was still significant after discharge from the index HF admission, suggesting the 
importance of adequate treatment of the index HF admission. Restoring SR and maintaining 
it during index HF admission appeared to affect not only the in-hospital outcomes but also 
the long-term outcomes over several years. 
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Limitations of the study 
There were several limitations to this study. This was a non-randomised, registry-
based study and might have been affected by unmeasured confounding factors. Since the 
attending physician’s intension regarding AF treatment strategy (rhythm control vs. rate 
control) was not collected in this registry, the definition of the present study groups is 
different from that of the rhythm and rate control strategy groups in previous randomized 
trials. The KorAHF registry did not collect data on the rhythm status during follow-up, thus 
further analysis according to the recurrence of AF during follow-up was not available. Further 
studies are warranted to confirm the effect of rhythm control strategies for AF in these high-
risk patients with AHF. 
 
CONCLUSIONS 
In this large multicenter KorAHF registry, patients with AHF and AF had 
significantly lower future mortality rates when rhythm treatments for AF were successfully 
applied. These results underscore the importance of restoring SR in patients presenting with 
AHF. 
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Table 1. Baseline characteristics. 
 Overall AF patients Matched population 
 
SR 
restored 
(n = 212) 
AF 
(n = 1,662) 
P 
SR 
restored 
(n = 167) 
AF 
(n = 501) 
P 
Age [years] 67 ± 14 71 ± 12 < 0.001 68 ± 13 68 ± 14 0.840 
Male 104 (49.1) 866 (52.1) 0.403 83 (49.7) 274 (54.7) 0.303 
Hypertension 114 (53.8) 999 (60.1) 0.077 91 (57.7) 226 (54.5) 0.528 
Diabetes mellitus 57 (26.9) 483 (29.1) 0.510 46 (27.5) 147 (29.3) 0.730 
CAD 37 (17.5) 346 (20.8) 0.262 32 (19.2) 116 (23.2) 0.333 
Valvular heart disease 41 (19.3) 393 (23.6) 0.162 32 (19.2) 77 (15.4) 0.304 
Cerebrovascular 
disease 
32 (15.1) 325 (19.6) 0.119 22 (13.2) 62 (12.4) 0.893 
CKD 17 (8.0) 197 (11.9) 0.098 14 (8.4) 43 (8.6) 1.00 
De novo heart failure 115 (54.2) 705 (42.4) 0.001 90 (53.9) 271 (54.1) 1.00 
Lung congestion 164 (77.4) 1303 (78.4) 0.729 112 (76.6) 410 (81.8) 0.176 
Previous HF 
admission 
65 (30.7) 652 (39.3) 0.019 52 (31.1) 147 (29.3) 0.732 
New onset AF 108 (51.9) 499 (30.4) < 0.001 85 (50.9) 261 (52.1) 0.858 
Tachycardia induced 
HF 
105 (49.5) 729 (43.9) 0.118 88 (52.7) 251 (50.1) 0.623 
CHA2DS2-VASc score 4.4 ± 1.7 4.8 ± 1.7 0.001 4.4 ± 1.7 4.4 ± 1.5 0.766 
Malignancy 21 (9.9) 132 (7.9) 0.326 16 (9.6) 39 (7.8) 0.569 
ICU admission 134 (63.2) 642 (38.6) < 0.001 99 (59.3) 297 (59.3) 1.00 
Mechanical ventilation 54 (25.5) 172 (10.3) < 0.001 33 (19.8) 98 (19.6) 1.00 
Hemoglobin [g/dL] 12.7 ± 2.2 12.7 ± 2.2 0.903 12.8 ± 2.2 12.8 ± 2.1 0.693 
Creatinine [mg/dL] 1.3 ± 1.4 1.3 ± 1.0 0.939 1.2 ± 0.9 1.3 ± 0.8 0.604 
High BNP or NT-
proBNP 
162 (88.0) 1220 (81.4) 0.034 128 (88.9) 424 (91.0) 0.557 
LVEF [%] 37 ± 16 41 ± 16 < 0.001 37 ± 17 36 ± 16 0.550 
LA dimension [mm] 49 ± 10 54 ± 10 < 0.001 50 ± 10 50 ± 8 0.882 
Discharge medication       
   ACEI or ARB 123 (58.0) 1062 (63.9) 0.110 102 (61.1) 323 (64.5) 0.486 
   Beta-blocker 99 (46.7) 802 (48.3) 0.723 78 (46.7) 270 (53.9) 0.128 
Data are expressed as number (%) or mean ± standard deviation. ACEI — angiotensin-converting enzyme 
inhibitor; AF — atrial fibrillation; ARB — angiotensin receptor blocker; BNP — B-type natriuretic peptide; 
CAD — coronary artery disease; CKD — chronic kidney disease; HF — heart failure; ICU — intensive care 
unit; LA — left atrium; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal-pro B-type 
natriuretic peptide; SR — sinus rhythm 
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Table 2. In-hospital outcomes. 
 Overall population 
 
Matched population 
 
SR  
(n = 212) 
AF  
(n = 
1,662) 
Unadjusted 
OR (95% 
CI) 
P 
Adjusted OR 
(95% CI) 
P 
 
SR  
(n = 167) 
AF  
(n = 501) 
Unadjusted 
OR (95% 
CI) 
P 
All-cause mortality 9 (4.2%) 70 (4.2%) 
1.01 (0.44–
2.07) 
0.982 
0.26 (0.08–
0.88) 
0.031 
 
5 (3.0%) 37 (7.4%) 
0.39 (0.15–
1.00) 
0.050 
Cardiovascular death 8 (3.8%) 50 (3.0%) 
1.26 (0.51–
2.74) 
0.545 
0.40 (0.11–
1.40) 
0.151 
 
5 (3.0%) 27 (5.4%) 
0.54 (0.21–
1.43)  
0.216 
Cerebral vascular 
accident 
2 (0.9%) 27 (1.6%) 
0.58 (0.07–
2.32) 
0.449 
0.56 (0.12–
2.65) 
0.465 
 
2 (1.2%) 7 (1.4%) 
0.86 (0.18–
4.16) 
0.847 
Odds ratios (OR) for in-hospital clinical outcomes of the sinus rhythm (SR) conversion group compared to the atrial fibrillation (AF) persistent group; CI — 
confidence interval 
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Table 3. Predictors for all-cause mortality at follow-up in an overall population.  
 Unadjusted HR 
(95% CI) 
P 
Conversion to sinus rhythm 0.70 (0.54–0.91) 0.007 
Age (per 1 year) 1.05 (1.04–1.05) < 0.001 
Male 1.05 (0.91–1.22) 0.481 
Hypertension 1.36 (1.17–1.59) < 0.001 
Diabetes 1.52 (1.31–1.77) < 0.001 
Ischemic heart disease 1.51 (1.28–1.79) < 0.001 
Valvular heart disease 1.34 (1.14–1.58) < 0.001 
Cerebrovascular disease 1.48 (1.25–1.76) < 0.001 
Chronic kidney disease 2.36 (1.96–2.85) < 0.001 
ADHF (vs. de novo) 1.77 (1.51–2.06) < 0.001 
Lung congestion 1.27 (1.06–1.54) 0.011 
Previous HF admission 1.80 (1.55–2.10) < 0.001 
New onset AF 0.80 (0.68–0.94) 0.007 
Tachycardia-induced HF 0.61 (0.52–0.71) < 0.001 
Malignancy 1.36 (1.07–1.73) 0.013 
ICU admission 1.27 (1.10–1.48) 0.001 
Mechanical ventilation 1.75 (1.43–2.14) < 0.001 
Hemoglobin (per 1 g/dL) 0.81 (0.79–0.84) < 0.001 
Creatinine (per 1 mg/dL) 1.17 (1.13–1.21) < 0.001 
High BNP or NT-proBNP 1.36 (1.09–1.68) 0.006 
LVEF > 40% 1.03 (0.88–1.20) 0.745 
LA (per 1 mm) 1.01 (1.00–1.01) 0.134 
ACEI or ARB at discharge 0.57 (0.49–0.65) < 0.001 
Beta-blocker at discharge 0.59 (0.51–0.68) < 0.001 
ADHF — acute decompensated heart failure; CI — confidence interval; HR — hazard ratio; other abbreviations as 
for Table 1 
 
 
 
 
16 
 
 
Table 4. Subgroup analysis for mortality in a matched population. 
  No. of patients 
Adjusted HR 
(95% CI) 
P 
Interaction 
P 
Age   
 65 years 429 0.43 (0.28–0.64) < 0.001 
0. 283 
< 65 years 239 0.78 (0.35–1.73) 0.549 
Gender  
Male 357 0.38 (0.23–0.65) < 0.001 
0. 139 
Female 311 0.63 (0.39–1.04) 0.068 
Diabetes mellitus  
Yes 193 0.64 (0.33–1.24) 0.184 
0.511 
No 475 0.48 (0.31–0.74) 0.001 
Hypertension  
Yes 380 0.34 (0.21–0.54) <0.001 
0.021 
No 288 0.89 (0.51–1.57) 0.703 
New-onset AF  
Yes 346 0.34 (0.19–0.60) < 0.001 
0. 216 
No 322 0.56 (0.34–0.91) 0.019 
Type of HF  
De novo 361 0.35 (0.19–0.65) < 0.001 
0.101 
ADHF 307 0.62 (0.39–0.99) 0.043 
Etiology of HF 
Ischemic 148 0.40 (0.18–0.86) 0.019 
0.229 
Non-ischemic 520 0.55 (0.36–0.83) 0.005 
Abbreviations as for Tables 1 and 3. 
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Figure 1. Flowchart of the study population; AAD — anti-arrhythmic drug; AF — atrial 
fibrillation; AHF — acute heart failure; DCC — direct current cardioversion; KorAHF — The 
Korean Acute Heart Failure registry. 
 
Figure 2. Clinical outcomes in overall study population; A. Mortality, B. Heart failure (HF) 
rehospitalization; (C) Composite of mortality and HF rehospitalization; AF — atrial fibrillation; 
CI — confidence interval; HR — hazard ratio; SR — sinus rhythm. 
 
Figure 3. Clinical outcomes in a propensity-score matched population; A Mortality; B. Heart 
failure (HF) rehospitalization; C. Composite of mortality and HF rehospitalization; abbreviations 
as for Figure 2.  



